Post by Vector BioMed, Inc.

As personalized medicine continues to accelerate, one quality has become essential to every new manufacturing platform: the know-how and flexibility to work with highly variable biologic systems.    In a recent Pharma's Almanac's roundtable, Vector BioMed CTO Andrew Worden expanded on that idea, offering his perspective on the tools shaping the next era of cell and gene therapy manufacturing: "The most important technologies are and will be flexible platforms that speed development, efficiencies, and release." From single-use systems to high-throughput analytics and refined vector design, flexibility is reshaping how quickly therapies move from process to patient. Andrew noted that platform technologies now sit at a critical inflection point... the next wave of optimization and integration will determine how efficiently cures reach those who need them. Read the full roundtable here: https://lnkd.in/g8JV4syn #CGT #GeneTherapy #LentiviralVectors #AdvancedTherapies